Join the Bosulif group to help and get support from people like you.
Bosulif News
FDA Approves Bosutinib for Pediatric Patients with Chronic Myelogenous Leukemia
September 27, 2023 – On September 26, 2023, the Food and Drug Administration approved bosutinib (Bosulif, Pfizer) for pediatric patients 1 year of age and older with chronic phase (CP) Ph+ chronic...
FDA Approves Pfizer’s Bosulif (bosutinib) for the Treatment of Patients with Newly-Diagnosed Ph+ Chronic Myelogenous Leukemia (CML)
December 19, 2017 – Pfizer Inc. (NYSE:PFE) today announced the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) to expand the indication for Bosulif...
Further information
Related condition support groups
Chronic Myelogenous Leukemia (CML)